Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 18139 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 18894 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 25816 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 25823 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 26551 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 27312 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 27835 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 27877 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 27957 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 31475 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 36486 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 40955 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 41152 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 42246 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 43531 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 48985 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 49451 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 49760 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 51827 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 53744 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 57521 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 61340 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 62917 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 64225 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 76347 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+ | 78757 | Peak area normalized | male | Diabetic | no neuropathy |